RYAH Group (CSE: RYAH) today announced that it has completed the first shipment of the RYAH Smart Dry Herb Inhalers, which includes a delivery of approximately 10,000 RYAH Cartridges and QR Codes to an international clinic undertaking one of the world’s largest and most comprehensive clinical trials in plant-based medicine. The initial shipment is designated to be used by the clinic in a pilot run in preparation for the previously announced, UK-based study on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. “We are pleased to bring RYAH’s IoT device and integrated data solutions to the United Kingdom, providing a new level of session accuracy, patient feedback consistency and data integrity to the clinical framework in plant-based medicine research,” said Gregory Wagner, CEO of RYAH Group. “We continue to evolve our product and software solutions to help clinicians and researchers unlock breakthroughs in clinical research and analytics.”
To view the full press release, visit https://ibn.fm/qg29M
About RYAH Group Inc.
RYAH is a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant patient data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is relevant for clinics, doctors, dispensaries, pharmaceutical companies, and licensed processors (“LPs”) to monitor and manage formulation effects on patient and demographics. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation lifecycle. For more information about the company, please visit www.RYAHGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
